3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
13
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Endometriosis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
209
Paclitaxel
187
Fulvestrant
161
Capecitabine
150
Docetaxel
136
Letrozole
127
exemestane
92
palbociclib
76
Anastrozole
75
Cyclophosphamide
71
Lapatinib
69
Gemcitabine
66
Bevacizumab
66
pertuzumab
61
pembrolizumab
60
ribociclib
59
Carboplatin
59
abemaciclib
53
eribulin
48
Doxorubicin
45
Vinorelbine
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Tamoxifen
40
130-nm albumin-bound paclitaxel
34
Injections
31
trastuzumab deruxtecan
30
Albumin-Bound Paclitaxel
26
olaparib
24
Alpelisib
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms
×
Atorvastatin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn